MIRAVANT - neuer Biotech-Highflyer? WKN 895726

PhotoPoint PDT combines minimally invasive drug and light to selectively destroy diseased cells and blood vessels. Because PhotoPoint drugs concentrate in rapidly reproducing cells, a phenomenon associated with a number of diseases, the technology has a range of potential applications.

Miravant's drug discovery programs have produced a PhotoPoint pipeline distributed across various stages of development from research to late-stage clinical trials.

-SnET2 Completed Phase III - age-related macular degeneration; NDA filing in preparation
-MV9411 Phase II - plaque psoriasis
-MV0633 Advanced preclinical - treatment of atherosclerotic vulnerable plaque and prevention of restenosis
-MV2101 Advanced preclincal - hemodialysis vascular access grafts, prevention of stenosis
-MV6401 Preclinical - solid tumors (treatment of cells & neovasculature)

Based on broad patented classes of photoreactive compounds, Miravant has generated a large inventory of novel drug candidates as well as innovative, easy-to-use light devices for physicians in outpatient and office settings. The company believes that its combined in-house capabilities in synthetic chemistry, biology and medical device engineering stand out in the PDT industry.

Miravant is pursuing a strategy of discovery, development and licensing of its PhotoPoint drugs and light devices, conducting rigorous preclinical and early clinical product testing and partnering for late-stage development and commercialization. As specialists in PDT technologies, Miravant is positioning itself to be a leading resource for pharmaceutical and medical device companies seeking entry into the expanding field of photoselective medicine.

There are approximately 25.5 million shares outstanding.

Miravant operates on a fiscal year ending December 31st. Our quarterly reporting period ends on March 31st, June 30th, September 30th, and December 31st. Earnings releases are tentatively scheduled for March 30, May 13, August 13 and November 12, 2003.

Investor Relations Contact Information:
336 Bollay Drive
Santa Barbara, California 93117
Phone: 805.685.9880
Fax: 805.685.7682

Tom Herrick - Manager, Investor Relations


Gruss
  cubiak

MRVT  Miravant Med Technologies $3.99

chart.bigcharts.com/bc3/intchart/frames/...nd=1648&mocktick=1" style="max-width:560px" alt="Chart von MRVT">

Chart sieht geil aus. Firma ist sehr interessant. Die haben eben nur noch kein Produkt auf dem Markt, was auch verkauft wird. Die letzte Meldung stimmt zuversichtlich. Der Chart sieht absolut nach Kauf aus. Aber vorsicht vor der Vola!


patzi

und Ariva wieder stärker frequentiert ist. Hat noch jemand Meinungen zu dieser Aktie bzw. Informationen?

Gruss und einen guten Start in die Woche.

cubiak

support further investigations of intravascular PhotoPoint PDT as a potential
treatment for atherosclerosis and vulnerable plaque, and we are working towards
human clinical trials."

Financings

As of December 31, 2003, the Company had borrowed $6.3 million under a 2002 Debt
Agreement that allows borrowings up to $1.0 million per month through June 2004,
not to exceed $12.0 million and subject to certain requirements. In August 2003,
the Company entered into a Convertible Debt and Warrant Purchase Agreement (2003
Debt Agreement) with a group of private accredited investors, pursuant to which
the Company received gross proceeds of $6.0 million. In September 2003, the
Company settled its $10.0 million debt with Pharmacia AB, a wholly owned
subsidiary of Pfizer, Inc., the terms of which included payments by the Company
of $1.0 million and 390,000 shares of its Common Stock. In December 2003, the
Company completed the sale of its investment in an affiliate, Xillix
Technologies Corporation, providing net cash proceeds of $1.6 million.
Subsequent to the end of fiscal year 2003, the Company issued debentures under a
$2.0 million Unsecured Convertible Debenture Purchase Agreement, resulting in
proceeds to the Company of $2.0 million. In addition, through the exercise of
warrants in fiscal 2004 related to the August 2003 Debt Agreement, the Company
has received proceeds of $1.4 million.

Ophthalmology Program: NDA Submission Planned for Wet AMD

In January 2003, Miravant announced its intention to submit its first NDA to the
U.S. Food and Drug Administration (FDA) seeking marketing approval of SnET2 as a
treatment for the wet form of AMD, a leading cause of blindness in older adults.
The Company expects to submit its NDA on or about March 31, 2004. The planned
NDA is based on the clinical results in the "per protocol" study population,
which consists of those patients who received the exposure to the SnET2
treatment regimen pre-specified in the clinical protocol. In November 2003,
clinical investigators presented the SnET2 Phase III clinical results for the
first time at the American Academy of Ophthalmology conference in Anaheim,
California.

Dermatology Program: PhotoPoint MV9411 in Phase II Study

During 2003, the Company continued a Phase II dose-escalation clinical trial of
topical drug MV9411 for the treatment of psoriatic plaques. Psoriasis is a
chronic skin condition in which the immune system triggers accelerated growth of
the epidermis, causing inflamed, scaly skin plaques. Miravant expects the Phase
II study to be completed in 2004 and then a determination will be made about
continuance of the program based on clinical trial results and available
resources.

Cardiovascular Program: Preclinical Results Presented at Major Scientific
Meetings

Miravant has several preclinical development programs underway to address large
potential markets in coronary artery disease, including the treatment of
atherosclerosis, atherosclerotic vulnerable plaque and the prevention and
treatment of restenosis. Miravant is also testing a local PhotoPoint treatment
to inhibit failure of vascular access grafts in hemodialysis patients. During
2003, key academic collaborators presented encouraging preclinical results for
all these programs at cardiovascular conferences, including Transcatheter
Cardiovascular Therapeutics, American College of Cardiology, International
Conference on Cardiovascular Medicine and Science, and Cardiovascular Radiation
Therapy.

Oncology Program: PhotoPoint PDT for Tumor Cells and Blood Vessels

During 2003, Miravant continued its preclinical research studies of PhotoPoint
MV6401 to treat solid tumor cells and the new blood vessels that support tumor
growth. The results of this research, if favorable, could lead to future
development programs in breast, lung, brain and/or prostate cancers.

About Miravant

Miravant Medical Technologies specializes in the development of pharmaceuticals
and devices for photoselective medicine, developing its proprietary PhotoPoint
photodynamic therapy (PDT) for large potential markets in ophthalmology,
dermatology, cardiovascular disease and oncology. PhotoPoint PDT uses
photoreactive (light-activated) drugs to selectively target diseased cells and
blood vessels. The Company has completed Phase III clinical trials of lead drug
SnET2 to treat wet AMD and plans to submit an NDA filing for this indication.
Miravant's cardiovascular program focuses on life-threatening diseases, with
PhotoPoint MV0633 in advanced preclinical testing for atherosclerosis,
atherosclerotic vulnerable plaque, and restenosis.

For more information, please visit our web site at: www.miravant.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

The statements contained in this press release that are not purely historical
are forward-looking statements within the meaning of Section 21E of the
Securities and Exchange Act of 1934, as amended, including but not limited to
those by Dr. Kledzik and other statements about the planned NDA submission of
SnET2 for the treatment of wet AMD; potential use of SnET2 to treat wet AMD; the
availability of the remaining $5.7 million under the line of credit through June
2004; potential applications of PhotoPoint PDT in cardiovascular disease,
dermatology and oncology and encouraging preclinical results; the size of
potential markets; and obtaining additional funding to support cardiovascular
programs. These forward-looking statements relate to our future plans,
objectives, expectations and intentions. The Company's actual results may differ
materially from those described in these statements. For instance, the
occurrence of one or more of the following may cause the Company's results to
differ from the Company's plans: the Company's operating capital may not be
sufficient to continue some or all of its development programs, complete the
planned NDA submission or continue as a going concern; potential future funding
may not be available when needed if at all or under terms acceptable to the
Company; the Company may not meet the requirements under the 2002 Debt Agreement
which could terminate the funding thereunder prior to June 2004; the Company may
not meet the covenants of the August 2003 Convertible Debt and Warrant Purchase
Agreement or the February 2004 Debt Agreement, which would give the holders
under these agreements the right to call outstanding debt immediately due and
payable; the FDA may not file the NDA submission for review; if the NDA
submission is reviewed, the Company may be unable to resolve all issues or
contingencies associated with it; the FDA may require further clinical or
non-clinical studies before granting marketing approval, or may limit labeling
claims, or may not grant approval at all; even if approved, the Company may not
have the necessary resources or corporate partnering relationship(s) to
commercialize SnET2 and the degree of acceptance of SnET2 cannot be guaranteed;
the Phase II dermatology clinical trial may prove to be unsuccessful and/or the
trial may not be completed when expected; the Company may decide not to or be
unable to further develop its PhotoPoint drugs in ophthalmology, dermatology,
cardiovascular disease and/or oncology; results of preclinical studies may not
be indicative of future clinical trials, if and when clinical trials begin; the
Company may not be able to demonstrate the safety or efficacy of its drugs in
development or achieve their regulatory approvals; and/or partnering discussions
may not progress or may not provide the funding and support the Company needs.
For a discussion of additional important risk factors that may cause the
Company's results to differ from those described above, please refer to
Miravant's annual report on Form 10-K for the year ended December 31, 2003,
which will be filed with the Securities and Exchange Commission on March 29,
2004, and other quarterly and periodic reports filed with the Securities and
Exchange Commission.

Dies ist ein Plus von gut zwei Prozent. Nachdem Miravant zu Handelsbeginn stark anstieg und danach Gewinnmitnahmen einsetzten, die den Kurs von 4,30 bis auf 3,93 drückten ist dies ein weiteres sehr positives Signal. Bei hohen Umsätzen haben starke Anschlusskäufe gezeigt, welches Interesse weiterhin besteht.

Kursziel auf 12 Monate: 15 Dollar! Wichtig vor allem, das das PhaseIII-Medikament seine Marktzulassung erhält. Dies ist aber mehr als wahrscheinlich. Mit diesem Medikament erschließt sich ein Markt von mehreren Milliarden Dollar.

Gruss
  cubiak

Über solch geile Aktien wird erst geredet, wenn sie sich dann verzehnfacht haben oder etabliert haben. Dann geht es wieder, och, hätte ich das gewusst. Hast du den Mut gefunden hier einzusteigen?!

Ich bin rein zu 2,75€. Sogar mit einer für meine Verhältnisse recht ansehnlichen Position. Jetzt warte ich ab. Für das Einsteigen ist es jetzt aber noch nicht zu spät. An schwachen Tagen kann man durchaus noch einsteigen. Ich erwarte allerdings eine Haltezeit von 2-3 Jahren. Auf 12 Monaten bleibe ich bei 15 Dollar! Danach: Open-End.
Habe mich intensiv mit dieser Aktie beschäftigt. Es passt alles!

Gruss
 cubiak

der gestern veröffentlichten Quartalszahlen!

California-Based Drug Development Firm Stanches Negative Cash Flow  

Mar 30, 2004 (Santa Barbara News-Press - Knight Ridder/Tribune Business News
via COMTEX) -- Miravant Medical Technologies continues losing money but the rate
has slowed, according to fourth-quarter financial results released Monday.

The Santa Barbara-based pharmaceutical development company, which specializes in
photodynamic therapy (highly specific light-activated drug treatments), lost
$1.6 million, or 6 cents per share, in the three months to the end of December.

This compares with a net loss of $4 million (16 cents per share) for the same
period in 2002. The company reported a net loss for the year of $7.5 million,
compared with $16 million for the whole of 2002.

Miravant had $1 million in cash at the end of December and $5.7 million
available under a debt agreement that provides up to $1 million monthly through
June 30, subject to certain requirements.

"Last year we continued to adhere to our cost-restructuring program, which has
helped reduce overall costs," said Gary Kledzik, chairman and chief executive
officer. "Our available resources were primarily directed toward the preparation
of Miravant's first new drug application, seeking marketing approval of
PhotoPoint SnET2 as a treatment for the wet form of (the eye disease)
age-related macular degeneration.

"We are very excited to be finalizing the documents for this submission, planned
on or about March 31," he said. "I am also proud of the progress we made last
year in other development programs, particularly our accomplishments in
cardiovascular studies."

In 2003 the company continued clinical trials of a topical drug for the
treatment of the chronic skin condition psoriasis. Miravant also has several
preclinical development programs under way to address coronary artery disease
and is continuing research studies in the treatment of breast, lung, brain and
prostate cancer tumors.

procedure. This device, the IRIS Medical OcuLight 664 Ophthalmic PDT Laser, was
co-developed by Miravant and Iridex Corporation (Nasdaq: IRIX), a leading
manufacturer of semi-conductor based diode lasers. SnET2-PDT is classified as a
combination drug and device product, and thus the NDA and PMA are reviewed by
the respective FDA drug and device divisions.

Gary S. Kledzik, Ph.D., chairman and chief executive officer, stated, "I would
like to recognize the very distinguished group of retinal specialists who
administered the SnET2 therapy in clinical research studies and the many
patients who volunteered to participate over the course of two years. We thank
them for their dedicated efforts in support of finding new treatments for this
serious eye disease.

"I am extremely proud of the quality and scope of Miravant's first NDA
submission, a milestone achievement after years of rigorous drug development,"
Dr. Kledzik added. "We are optimistic that, if approved by the FDA, SnET2-PDT
may allow physicians in the future to treat a broader range of patients, with a
shorter and more well defined treatment regimen than currently available."

Profound Need for AMD Treatments

Choroidal neovascularization associated with age-related macular degeneration is
a major health problem in the United States and other parts of the world. At the
present time, an estimated eight million persons at least 55 years old in the
U.S. are considered to have AMD at high risk for progression to advanced
neovascular ("wet") AMD, characterized by subfoveal CNV. Of these at-risk
individuals, it is estimated that over the next five years, 1.35 million within
the U.S. will develop wet AMD, with similar numbers in Europe and the rest of
the world. Other estimates of the prevalence suggest that there may be as many
as 12 million individuals within the U.S. with early and late stage AMD. The
aging of the population suggests that this disease will become an
ever-increasing medical, social and economic problem over the coming years.

Persons with wet AMD can experience significant reductions in vision and need
assistance with daily activities. These individuals can be profoundly distressed
and are often characterized as disabled, with severe reduction in their quality
of life. In spite of the prevalence and severity of this disease, there are
limited treatment options, and for most patients there is an unmet need for
therapy.

About Miravant

Miravant Medical Technologies specializes in the development of pharmaceuticals
and devices for photoselective medicine, developing its proprietary PhotoPoint
photodynamic therapy (PDT) for large potential markets in ophthalmology,
dermatology, cardiovascular disease and oncology. PhotoPoint PDT uses
photoreactive (light-activated) drugs to selectively target diseased cells and
blood vessels.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

The statements contained in this press release that are not purely historical
are forward-looking statements within the meaning of Section 21E of the
Securities and Exchange Act of 1934, as amended, including but not limited to
those by Dr. Kledzik and other statements about potential FDA approval of
SnET2-PDT to treat classic wet AMD lesions; the safety and efficacy results of
SnET2-PDT; potential clinical use and treatment benefits of SnET2-PDT; FDA
agreeing to file the NDA within 60 days of submission; FDA granting priority
review status; FDA completing NDA review within six months of filing; the
potential size of the classic wet AMD market; and potential applications of
PhotoPoint PDT in ophthalmology, cardiovascular disease, dermatology and
oncology are forward-looking and relate to our future plans, objectives,
expectations and intentions. The Company's actual results may differ materially
from those described in these statements. For instance, the occurrence of one or
more of the following may cause the Company's results to differ from the
Company's plans: the Company's operating capital may not be sufficient to
continue some or all of its development programs, complete the NDA review
process, conduct additional clinical or pre-clinical studies required by the
FDA, commercialize SnET2-PDT or continue as a going concern; potential future
funding may not be available when needed if at all or under terms acceptable to
the Company; the FDA may refuse to file the NDA submission for review; the FDA
may not grant priority review status; the Company may be unable to resolve all
issues or contingencies associated with the NDA review; the FDA may require
further clinical or non-clinical studies before granting marketing approval, or
may limit labeling claims, or may not grant approval at all; even if approved,
the FDA may require the Company to conduct post-market clinical studies; even if
approved, the Company may not have the necessary resources or corporate
partnering relationship(s) to commercialize SnET2-PDT, and the degree of
acceptance of SnET2-PDT cannot be guaranteed; the estimated size of the classic
wet AMD market may prove to be incorrect or may change with time; the medical
need in this market may be satisfied by competitive treatments; the results of
the SnET2 Phase III clinical studies may not be indicative of future clinical
results; the Company may not be able to demonstrate the safety or efficacy of
its drugs in development or achieve their regulatory approvals; and/or
partnering discussions may not progress or may not provide the funding and
support the Company needs. For a discussion of additional important risk factors
that may cause the Company's results to differ from those described above,
please refer to Miravant's annual report on Form 10-K for the year ended
December 31, 2003, filed with the Securities and Exchange Commission, and other
quarterly and periodic reports filed with the Securities and Exchange
Commission.

SOURCE: Miravant Medical Technologies

growth of fluorescein leakage, subretinal fluid, choroidal neovascularization
(CNV) and total lesion area relative to placebo at all time points during the
two-year studies.

"Vessel leakage and the resultant subretinal fluid accumulation are considered
to be indicative of disease activity in patients with macular degeneration," Dr.
Danis stated. "I believe it is very important that the SnET2 treatment clearly
reduced these physiologic processes. The angiographic assessments support the
primary visual acuity outcome that SnET2 significantly reduced the risk of
vision loss in drug-treated AMD patients versus placebo patients."

Carl Regillo MD, Wills Eye Hospital, Philadelphia PA, presented safety results
in the total study population. Dr. Regillo concluded, "SnET2 demonstrated an
excellent safety profile. The treatments were well tolerated in study
population, with a very low overall incidence of treatment-related adverse
events."

Kapitalerhöhung ohne Probleme abgeschlossen! STRONG BUY :-)

SANTA BARBARA, Calif., Apr 27, 2004 (BUSINESS WIRE) -- Miravant Medical
Technologies (OTCBB: MRVT), a pharmaceutical development company specializing in
PhotoPoint(R) photodynamic therapy (PDT), announced today that it has closed a
$10,269,000 private placement of 4,564,000 shares of common stock with a group
of institutional investors, with full proceeds to the Company. There were no
warrants or placement fees associated with the offering. The funds will be used
for general corporate purposes.

Lauderdale FL. In two independent phase III clinical trials of patients with wet
AMD, SnET2 demonstrated a visual acuity benefit and slowed the progression of
problematic vascular lesions in the per protocol study population, the basis of
the NDA submission.

Also in March, scientific results of the Company's cardiovascular program were
presented at the American College of Cardiology (ACC), New Orleans LA. The
development program focuses on the treatment of life-threatening coronary artery
diseases, including atherosclerosis and atherosclerotic vulnerable plaque. In a
series of preclinical studies conducted in atherosclerosis models, PhotoPoint
PDT has been demonstrated to remove problematic inflammatory cells in
atherosclerotic plaque, reduce plaque volume and induce healing and repair of
vessel walls.

About Miravant

Miravant Medical Technologies specializes in pharmaceuticals and devices for
photoselective medicine, developing its proprietary PhotoPoint photodynamic
therapy (PDT) for large potential markets in ophthalmology, dermatology,
cardiovascular disease and oncology. PhotoPoint PDT uses photoreactive
(light-activated) drugs to selectively target diseased cells and blood vessels.
The Company has submitted an NDA for the drug SnET2 for the treatment of
patients with wet AMD. Miravant's cardiovascular program focuses on
life-threatening diseases, with PhotoPoint MV0633 in advanced preclinical
testing for atherosclerosis, atherosclerotic vulnerable plaque and restenosis.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

The statements contained in this press release that are not purely historical
are forward-looking statements within the meaning of Section 21E of the
Securities and Exchange Act of 1934, as amended, including but not limited to
those by Dr. Kledzik and other statements about the NDA submission of SnET2 for
the treatment of wet AMD; potential use and benefits of SnET2 to treat wet AMD;
potential applications of PhotoPoint PDT in cardiovascular disease and
encouraging preclinical results; and development programs for large potential
markets in ophthalmology, dermatology, cardiovascular disease and oncology are
forward-looking and relate to our future plans, objectives, expectations and
intentions. Our actual results may differ materially from those described in
these statements. For instance, the occurrence of one or more of the following
may cause our results to differ from our plans: the Company's operating capital
may not be sufficient to continue some or all of its development programs,
complete the NDA review process or continue as a going concern; potential future
funding may not be available when needed if at all or under terms acceptable to
the Company; the Company may not meet the covenants of the December 2002 Debt
Agreement, the August 2003 Convertible Debt and Warrant Purchase Agreement or
the February 2004 Debt Agreement, which would give the holders under these
agreements the right to call outstanding debt immediately due and payable; the
FDA may not agree to file the NDA submission for review; if reviewed, the
Company may be unable to resolve all issues or contingencies associated with the
NDA; the FDA may require further clinical or non-clinical studies before
granting marketing approval, or may limit labeling claims, or may not grant
marketing approval at all; even if approved, the Company may not have the
necessary resources or corporate partnering relationship(s) to commercialize
SnET2 and the degree of acceptance of SnET2 cannot be guaranteed; results of
cardiovascular preclinical studies may not be indicative of future clinical
trials, if and when clinical trials begin; the Company may decide not to or may
be unable to further develop its PhotoPoint drugs in ophthalmology, dermatology,
cardiovascular disease and/or oncology; the Company may not be able to
demonstrate the safety or efficacy of its drugs in development or achieve their
regulatory approvals; and/or partnering discussions may not progress or may not
provide the funding and support the Company needs. For a discussion of
additional important risk factors that may cause our results to differ from
those described above, please refer to our annual report on Form 10-K for the
year ended December 31, 2003, our quarterly report on Form 10-Q for the quarter
ended March 31, 2004, and other quarterly and periodic reports filed with the
Securities and Exchange Commission. Our products require regulatory approval
before marketing, sales or clinical use. PhotoPoint(R) is a registered trademark
of Miravant Medical Technologies.



                    Miravant Medical Technologies

           Condensed Consolidated Statements of Operations

                             (Unaudited)



                                            3/31/04       3/31/03



Revenues                                        $ --          $ --



Cost and expenses:

 Research and development                 2,261,000     1,875,000

 General and administrative               1,724,000     1,373,000

Total costs and expenses                   3,985,000     3,248,000



Loss from operations                      (3,985,000)   (3,248,000)



Interest and other income (expense):

 Interest and other income                   20,000        20,000

 Interest expense                        (1,538,000)     (106,000)

 Gain (loss) on sale of assets                9,000       (18,000)

Total net interest and other expense      (1,509,000)     (104,000)



Net loss                                 $(5,494,000)  $(3,352,000)

Net loss per share -- basic and diluted       $(0.20)       $(0.14)

Shares used in computing net loss

per share                                27,251,824    24,250,735





                   Selected Condensed Consolidated

                         Balance Sheet Data



                                      As of 3/31/04      As of

                                       (Unaudited)      12/31/03





Cash and cash equivalents                $ 1,162,000   $ 1,030,000

Total current assets                       1,975,000     1,328,000

Total assets                               3,076,000     2,405,000



Total current liabilities                  2,592,000     1,992,000

Total liabilities                         11,465,000     9,432,000

Total stockholders' equity (deficit)      (8,389,000)   (7,027,000)

Total liabilities and stockholders'

equity (deficit)                        $ 3,076,000   $ 2,405,000

SOURCE: Miravant Medical Technologies



CONTACT:          Miravant Medical Technologies

                 John Philpott, Chief Financial Officer

                 Tom Herrick, Investor Relations

                 805-685-9880

warum in die USA gehen. So ähnliche Firmen gibt es auch in D.
KE vor Annahme - Wert ist noch nicht angelaufen !
Vielversprechendes Produkt        
     -

Werde den angesprochenen Wert mal genauer unter die Lupe nehmen...

gruss
 cubiak

Tagen. man bin ich froh, dass ich vor zwei Tagen meinen Einstandskurs auf 2,25 verbilligen konnte, als ich nochmals bei 1,75 nachgekauft habe. Ich denke, die positiven News zur NDA stehen an. Sicherlich ist der Kursanstieg Spekulation. Aber vielleicht wissen einige mehr...

Und die Umsaetze sind gewaltig!!!

Miravant's SnET2 New Drug Application Accepted for Filing by FDA with Priority Review Designation  


SANTA BARBARA, Calif., Jun 1, 2004 (BUSINESS WIRE) -- Miravant Medical
Technologies (OTCBB: MRVT), a pharmaceutical development company specializing in
PhotoPoint(R) photodynamic therapy (PDT), announced today that the U.S. Food and
Drug Administration (FDA) has accepted for filing the Company's New Drug
Application (NDA) for SnET2 and has also granted a Priority Review designation.
Acceptance of the filing means that the FDA has made a determination that the
NDA meets the standard for substantive review, and the Priority Review
designation expedites the review period. Miravant is seeking approval from the
FDA for its proprietary new drug SnET2 as a treatment for patients with wet
age-related macular degeneration (AMD), a leading cause of blindness in older
adults.